Series: Cardiovascular outcome trials for diabetes drugs
Degludec and DEVOTE

MILES FISHER

Abstract
DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardio-vascular Events) was an FDA-mandated cardiovascular outcome trial and was the first – and at present the only – completed trial comparing two insulins. DEVOTE compared insulin degludec and insulin glargine (U100) in 7,637 people with type 2 diabetes with established cardiovascular disease, chronic kidney disease, or both, and older diabetic patients with increased cardiovascular risk. DEVOTE demonstrated non-inferiority for major cardiovascular events (MACE), a composite of death from cardiovascular causes, non-fatal myocardial infarction and non-fatal stroke, with a pre-specified non-inferiority margin of 1.3. At 24 months the mean HbA1c was similar in the two groups. Mean fasting plasma glucose was significantly lower in the degludec group than in the glargine group, and pre-specified severe hypoglycaemia was also significantly lower in the degludec group. DEVOTE satisfied the FDA cardiovascular safety requirements for new antidiabetic therapies.

Key words: diabetes, cardiovascular outcome trial, degludec, glargine

Introduction
Between 2008 and 2020 the licensing requirements for new antidiabetic drugs for the FDA in the USA usually required a dedicated cardiovascular outcome trial (CVOT) to satisfy criteria for cardiovascular safety.1 The primary endpoints were atherosclerotic events, either major cardiovascular events (MACE; a composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke), or major cardiovascular events plus hospitalisation for unstable angina. The study design could either be the new antidiabetic drug versus placebo or the new drug versus an active comparator, and most CVOTs used a placebo comparator group. Dedicated CVOTs have been performed for several drugs within the dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose co-transporter-2 (SGLT2) inhibitor drug classes. The outcomes for the first seven of these CVOTs have previously been reviewed in this series, describing the primary endpoint plus important secondary outcomes and subsequent publications of data from subgroups and post hoc analyses.2-8 The ORIGIN trial, completed in 2012, was an investigator-initiated CVOT comparing glargine with placebo in subjects with type 2 diabetes or prediabetes.9 ORIGIN used a study design that was similar to FDA-mandated CVOTs. DEVOTE was the first FDA-mandated CVOT of an insulin and compared insulin degludec with glargine.10

Background
Degludec is an ultralong-acting once daily basal analogue insulin. It was recommended for approval by the European Medicines Agency in 2012 in formulations of 100 units/mL (U100) and 200 units/mL (U200). It was submitted to the FDA at a similar time, but the FDA advisory committee thought that there was a consistent and persistent signal of excess cardiovascular risk associated with degludec relative to comparators, based on meta-analysis of cardiovascular events from the Phase 2 and Phase 3 development programme. The FDA requested a dedicated double-blind CVOT with glargine as the comparator. Degludec was approved for use in the USA following a resubmission in 2015, based on interim analysis of data from DEVOTE, and the DEVOTE study was completed in 2017.

DEVOTE
A paper describing the design and baseline characteristics of DEVOTE was published in 2016.11 The principal DEVOTE results were presented in 2017 at a meeting of the American Diabetes Association with simultaneous publication in the New England Journal of Medicine.12 The design of the study and key baseline characteristics are shown in Box 1.

In DEVOTE, the primary outcome of MACE, a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, occurred in 8.5% of the degludec group and 9.3% of the glargine group, demonstrating non-inferiority with a pre-specified upper boundary of the 95% confidence interval less than 1.3, but not superiority. This satisfied the FDA cardiovascular safety criteria from 2008 where a post-marketing trial was required to definitely show that the upper bound of the two-sided 95% confidence interval for the estimated risk ratio was less than 1.3. There was no difference in an expanded primary
The DEVOTE population was divided into quartiles of Degludec. Long-term modelling suggested that degludec was cost effective. A history of heart failure was a risk factor for chronic kidney disease. 63% of subjects were aged 60 years and had established cardiovascular disease. 16% chronic kidney disease and 21% established cardiovascular disease plus chronic kidney disease. 14% of subjects were aged 60 years and had risk factors for cardiovascular disease. 12% of subjects had baseline heart failure. 16% of subjects were not on insulin at baseline, 38% were on basal insulin only and 46% were on basal-bolus insulin, including bolus only insulin and premixed insulin. 60% of subjects were on metformin, 29% sulfonylureas, 12% DPP-4 inhibitors, 8% GLP-1 receptor agonists, 2% SGLT2 inhibitors. There were no statistically significant differences between the two groups.

**Box 1** Key features of DEVOTE

- DEVOTE compared degludec with glargine in a treat-to-target trial in 7,637 subjects with type 2 diabetes for 24 months
- The target was a pre-breakfast self-measured blood glucose concentration of 4.0–5.0 mmol/L, with a target of 5.0–7.0 mmol/L for vulnerable patients
- The mean age of subjects was 65 years with a mean duration of diabetes 16 years
- Mean baseline HbA1c was 8.4% (68 mmol/mol) falling to 7.5% (58 mmol/mol) at 24 months
- 63% of subjects were aged ≥50 years and had established cardiovascular disease, 16% chronic kidney disease and 21% established cardiovascular disease plus chronic kidney disease. 14% of subjects were aged ≥60 years and had risk factors for cardiovascular disease. 12% of subjects had baseline heart failure.
- 16% of subjects were not on insulin at baseline, 38% were on basal insulin only and 46% were on basal-bolus insulin, including bolus only insulin and premixed insulin. 60% of subjects were on metformin, 29% sulfonylureas, 12% DPP-4 inhibitors, 8% GLP-1 receptor agonists, 2% SGLT2 inhibitors.

**Box 2** Results of the DEVOTE trial

**Principal result**
- No difference in major adverse cardiovascular events (MACE)

**Other results from DEVOTE**
- Severe hypoglycaemia was significantly reduced in the degludec group with 280 events in 187 patients versus 472 events in 252 patients in the glargine group.
- The strongest risk factor for hospitalisation for heart failure (HHF) was prior heart failure, and the risk of HHF increased significantly within a week of an episode of severe hypoglycaemia.
- There was a non-significant increase in MACE in subjects who had experienced severe hypoglycaemia, and no temporal relationship between severe hypoglycaemia and MACE.
- Patients with increasing age had higher risks of cardiovascular death and all-cause mortality, with non-significant increases in MACE and severe hypoglycaemia.
- The DEVOTE population was divided into quartiles of hypoglycaemia risk and, in the group with the highest risk, severe hypoglycaemia was associated with a high incidence of MACE and all-cause mortality, and those treated with degludec had a lower incidence of MACE.
- The risks of MACE, cardiovascular death and all-cause mortality increased with worsening glomerular filtration rate.
- A history of heart failure was a risk factor for chronic kidney disease, as was a history of hepatic impairment.
- Long-term modelling suggested that degludec was cost effective from the perspective of England’s National Health Service in basal-bolus regimens for patients with type 2 diabetes at high cardiovascular risk.

**Discussion**

The DEVOTE trial demonstrated no significant differences in cardiovascular events between insulin degludec and insulin glargine. Glargine was chosen as an active comparator in a double-blind trial as several of the phase 3 studies with degludec used open-label glargine as the comparator, and cardiovascular endpoint data were available for glargine from the ORIGIN trial. Although the ORIGIN trial was similar to an FDA-mandated trial, there were several key differences: in ORIGIN many subjects had pre-diabetes or newly diagnosed diabetes and the mean duration of diabetes for people with prior diabetes was 5 years. ORIGIN compared glargine with placebo, and cancers were also compared in addition to cardiovascular outcomes, microvascular outcomes, incident diabetes, hypoglycaemia and weight. The
Key messages

- DEVOTE was the first FDA-mandated cardiovascular outcome trial comparing two insulins
- DEVOTE compared insulin degludec with insulin glargine and there were no differences in cardiovascular events
- Using a treat-to-target approach, degludec was associated with fewer episodes of severe hypoglycaemia than glargine

Reduction in severe and nocturnal hypoglycaemia comparing degludec with glargine U100 that was seen in the DEVOTE trial mirrors similar differences in hypoglycaemic events that were demonstrated in the SWITCH 1 and SWITCH 2 trials, which compared rates of symptomatic hypoglycaemia with degludec versus glargine U100 in randomised double-blind trials in people with type 1 and type 2 diabetes, respectively.13,14

Conflict of interest The authors report personal fees from Allergan, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Mylan, NAPP, Novo Nordisk, Sanofi and from Servier outside the submitted work.

Funding None.

References


VOLUME 21 ISSUE 1 • JUNE 2021 115